SEC Tracker
Get the app

Gracell Biotechnologies

OrbiMed New Horizons Master Fund (Shareholder) plans to sell 305,748 shares, about $1.8M

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Jun 15, 2023
  2. Broker: Themis Trading LLC
  3. Shares acquired by: Private placement

All of OrbiMed New Horizons Master Fund's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Gracell Biotechnologies files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.